Akt sensitization of cancer cells
Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type p53. Breast, ovarian, lung cancer and leukemia cells lines were treated with combinations of Akt activation inhibitor Triciribine (TCN) or Triciribine phosphate (TCNP) and chemotherapeutic drugs to determine the efficiency of combination therapy. Additionally, cells were introduced into xenograft models to determine in vivo effects of combination treatment. Combining TCN or TCNP with other anticancer drugs overcame cytotoxic or treatment resistance. Thus, TCN and TCNP are shown to broaden the spectrum of human tumors that can be effectively treated.
1. A method of treating cisplatin or carboplatin resistant cancer comprising the steps of:
administering a therapeutically effective amount of a combination of two compounds to a patient having cisplatin or carboplatin resistant cancer, wherein
a first of the two compounds is an effective dose of cisplatin or carboplatin; and
a second of the two compounds being an effective dose of Akt inhibitor,
wherein the two compounds act synergistically to induce apoptosis of cancer cells.
2. The method of claim 1 wherein the first of two compounds is cisplatin.
3. The method of claim 1 wherein the Akt inhibitor is Triciribine, Triciribine Phosphate, or API-2.
4. A method of treating cisplatin or carboplatin resistant cancer comprising administering a therapeutically effective amount of a combination of compounds to a patient having cisplatin or carboplatin resistant cancer, wherein:
the first compound is an effective dose of cisplatin; and
the second compound is an effective dose of an Akt inhibitor wherein the Akt inhibitor is API-2;
wherein the two compounds act synergistically to induce apoptosis of cancer cells.
5. A method of treating cisplatin or carboplatin resistant cancer comprising administering a therapeutically effective amount of two compounds to a patient having cisplatin or carboplatin resistant cancer, wherein:
the first compound is an effective dose of cisplatin or carboplatin; and
the second compound is an effective dose of Triciribine or Triciribine phosphate.